Cocooning Therapeutic Cells

茧化治疗细胞

• 批准号: 478517-2015
• 负责人: Godin, Michel
• 金额: $ 6.4万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=579575
• 关键词: Cocooning; Therapeutic; Cells

Medical therapies using undifferentiated cells (stem and progenitor) are emerging and are defining a new era in regenerative medicine. Our proposed research study targets the development of a cell encapsulation process for delivery to patients suffering from severe life-threatening disorders. Specifically, we are working with Northern Therapeutics, a Canadian biotechnology company that has developed new and effective autologous cell therapies for pulmonary diseases. A fundamental limitation to new cell therapies is the currently cumbersome cell pre-conditioning process that limits the widespread commercialization of their technology. To address this unmet and critical cell processing need, we have assembled a team of researchers from both physics and the life sciences to develop a scalable microfluidics-based stem cell encapsulation procedure that will allow for the rapid and reproducible manufacture of single-cell capsules. These capsules will be supplemented with novel biomimetic matrices that include bionanoparticles specifically designed to enhance cell function and organ-specific engraftment, and this way enhance the therapeutic effect of the cells. If successful this research will be widely applicable to the field of regenerative medicine, be of marked benefit to chronically ill patients, aide in the global competitiveness of a Canadian company, and stimulate economic development in Canada in an emerging new market.

使用未分化细胞(干细胞和祖细胞)的医学疗法正在出现，并正在定义再生的新纪元。 医药。我们建议的研究目标是开发一种细胞封装工艺，以供患者使用 患有严重的危及生命的疾病。具体地说，我们正在与北方治疗公司合作，一家加拿大公司 一家生物技术公司，已经为肺部疾病开发了新的有效的自体细胞疗法。一个 新细胞疗法的根本限制是目前繁琐的细胞预适应过程，这限制了 他们的技术广泛的商业化。为了满足这一未得到满足的关键信元处理需求，我们有 汇集了一组来自物理学和生命科学的研究人员，开发了一种可扩展的基于微流控的干细胞 封装程序，将允许快速和可重复地制造单细胞胶囊。这些胶囊 将由新型仿生基质补充，其中包括专门设计用于增强细胞的生物纳米颗粒 功能和器官特异性植入，这种方式增强了细胞的治疗效果。如果这项研究成功了 将广泛应用于再生医学领域，对慢性病患者有明显的好处，有助于 一家加拿大公司的全球竞争力，并刺激加拿大经济发展在一个新兴的新 市场。